A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
This is the first major brand refresh of CanSinoBIO since its inception in 2009
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
It is a multi-speciality healthcare brand which delivers a hassle-free experience for all types of cosmetic procedures and elective surgeries with personalized care
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
April 25th is commemorated as World Malaria Day
Access Healthcare for Medical Products (Access Healthcare) provides pharmaceutical companies with innovative marketing and sales solutions in the MENA (Middle East & North Africa) region
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
Heavy bleeding after giving birth is globally a leading cause of death in new mothers
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
Subscribe To Our Newsletter & Stay Updated
